ZEVRA THERAPEUTICS INC. - COMMON STOCK

Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

09 Jul 2024 09:00:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Expands Executive Leadership Team

25 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

18 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting

03 Jun 2024 11:00:00 By Nasdaq GlobeNewswire

Zevra Therapeutics to Participate at Upcoming Investor Events

09 May 2024 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

08 May 2024 07:00:01 By Nasdaq GlobeNewswire

Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024

01 May 2024 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

29 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting

15 Apr 2024 17:01:44 By Nasdaq GlobeNewswire

Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility

10 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

28 Mar 2024 16:32:04 By Nasdaq GlobeNewswire

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

26 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

25 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024

18 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

04 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics to Participate at Upcoming Investor Conferences

28 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors

23 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

08 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer

04 Jan 2024 08:55:49 By Nasdaq GlobeNewswire